
A real-world study on type 2 diabetes patients reveals dapagliflozin's potential in reducing the risk of nonvalvular atrial fibrillation compared to empagliflozin. The analysis, involving 137,928 patients, employs propensity-score matching and active-comparator design, showing a significant decrease in incident atrial fibrillation risk with dapagliflozin in both low and high cardiovascular risk groups. Results remain consistent across age, sex, body mass index, diabetes duration, and renal function. This suggests dapagliflozin's favorable impact on atrial fibrillation risk, emphasizing its potential cardiovascular benefits for individuals with type 2 diabetes.
Like
Save
Share